BONT/A FOR USE IN TREATING A FACIAL DYSTONIA

Abstract: the present invention is directed to a modified botulinum neurotoxin a (bont/a) for use in treating a facial dystonia, including blepharospasm and hemifacial spasm, wherein the unit dose of the modified bont/a is at least 240 pg of modified bont/a, wherein the modified bont/a is administered by intramuscular injection to an affected muscle of a subject, wherein the total dose administered during the treatment is greater than 24,000 pg and up to 82,500 pg (e.g. up to 75,000 pg) of the modified bont/a, and wherein the modified bont/a comprises a bont/a light-chain and translocation domain (hn), and a bont/b receptor binding domain (hc domain).

Inventor(s): Laurent Pons, Nicolae Grigore, Fatima Afzal Chowdhry

CPC Classification: A61K38/4893 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; soap compositions ))

Search for rejections for patent application number 20250213662